Corning Jerry Pharmaceutical-B (09966): JSKN027 IND application officially accepted by CDE

Zhitong Finance App News, Corning Jerry Pharmaceutical-B (09966) announced that the company's self-developed procedural death ligand 1 (PD-L1) /vascular endothelial growth factor receptor 2 (VEGFR2) bispecific antibody conjugate drug (ADC (s)) JSKN027 New Drug Clinical Trial (IND) application has been officially accepted by the National Drug Administration (NMPA) Drug Evaluation Center (CDE). The company plans to conduct a phase I clinical study of JSKN027 for the treatment of advanced malignant solid tumors, with the aim of evaluating its safety, tolerability, pharmacokinetics, pharmacodynamic characteristics and initial anti-tumor activity in such patient populations, and determining the maximum tolerable dose and/or recommended phase II dose.

Currently, no ADC targeting VEGFR2 alone or targeting PD-L1 and VEGFR dual pathways at the same time has entered clinical research worldwide. JSKN027 is the world's first PD-L1/VEGFR2 dual antibody ADC drug to enter clinical research. Preclinical data showed that JSKN027 showed significant tumor inhibitory activity in both in vitro and in vivo models. GLP toxicology studies have shown that the drug is well tolerated at the highest doses. Based on its multiple action mechanisms such as cytotoxic killing, anti-angiogenesis, and immunomodulation, JSKN027 is expected to provide new treatment options for various solid tumors.